This study clarified CEA ≥ 53.74 ng/ml, SCC − Ag ≥ 1.49 ng/ml, IL − 10 ≥ 16.95 pg/ml, and IL − 6 ≥ 0.76 pg/ml were risk factors impacting the efficacy of LC immunotherapy, indicating that elevated tumor markers and inflammation could affect the efficacy of immunotherapy in patients. The gene discussed is CEACAM5; the disease is neoplasm.